Characteristics of Salmonella Recovered From Stools of Children Enrolled in the Global Enteric Multicenter Study.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
16 08 2021
Historique:
received: 06 08 2020
accepted: 21 01 2021
pubmed: 26 1 2021
medline: 23 9 2021
entrez: 25 1 2021
Statut: ppublish

Résumé

The Global Enteric Multicenter Study (GEMS) determined the etiologic agents of moderate-to-severe diarrhea (MSD) in children under 5 years old in Africa and Asia. Here, we describe the prevalence and antimicrobial susceptibility of nontyphoidal Salmonella (NTS) serovars in GEMS and examine the phylogenetics of Salmonella Typhimurium ST313 isolates. Salmonella isolated from children with MSD or diarrhea-free controls were identified by classical clinical microbiology and serotyped using antisera and/or whole-genome sequence data. We evaluated antimicrobial susceptibility using the Kirby-Bauer disk-diffusion method. Salmonella Typhimurium sequence types were determined using multi-locus sequence typing, and whole-genome sequencing was performed to assess the phylogeny of ST313. Of 370 Salmonella-positive individuals, 190 (51.4%) were MSD cases and 180 (48.6%) were diarrhea-free controls. The most frequent Salmonella serovars identified were Salmonella Typhimurium, serogroup O:8 (C2-C3), serogroup O:6,7 (C1), Salmonella Paratyphi B Java, and serogroup O:4 (B). The prevalence of NTS was low but similar across sites, regardless of age, and was similar among both cases and controls except in Kenya, where Salmonella Typhimurium was more commonly associated with cases than controls. Phylogenetic analysis showed that these Salmonella Typhimurium isolates, all ST313, were highly genetically related to isolates from controls. Generally, Salmonella isolates from Asia were resistant to ciprofloxacin and ceftriaxone, but African isolates were susceptible to these antibiotics. Our data confirm that NTS is prevalent, albeit at low levels, in Africa and South Asia. Our findings provide further evidence that multidrug-resistant Salmonella Typhimurium ST313 can be carried asymptomatically by humans in sub-Saharan Africa.

Sections du résumé

BACKGROUND
The Global Enteric Multicenter Study (GEMS) determined the etiologic agents of moderate-to-severe diarrhea (MSD) in children under 5 years old in Africa and Asia. Here, we describe the prevalence and antimicrobial susceptibility of nontyphoidal Salmonella (NTS) serovars in GEMS and examine the phylogenetics of Salmonella Typhimurium ST313 isolates.
METHODS
Salmonella isolated from children with MSD or diarrhea-free controls were identified by classical clinical microbiology and serotyped using antisera and/or whole-genome sequence data. We evaluated antimicrobial susceptibility using the Kirby-Bauer disk-diffusion method. Salmonella Typhimurium sequence types were determined using multi-locus sequence typing, and whole-genome sequencing was performed to assess the phylogeny of ST313.
RESULTS
Of 370 Salmonella-positive individuals, 190 (51.4%) were MSD cases and 180 (48.6%) were diarrhea-free controls. The most frequent Salmonella serovars identified were Salmonella Typhimurium, serogroup O:8 (C2-C3), serogroup O:6,7 (C1), Salmonella Paratyphi B Java, and serogroup O:4 (B). The prevalence of NTS was low but similar across sites, regardless of age, and was similar among both cases and controls except in Kenya, where Salmonella Typhimurium was more commonly associated with cases than controls. Phylogenetic analysis showed that these Salmonella Typhimurium isolates, all ST313, were highly genetically related to isolates from controls. Generally, Salmonella isolates from Asia were resistant to ciprofloxacin and ceftriaxone, but African isolates were susceptible to these antibiotics.
CONCLUSIONS
Our data confirm that NTS is prevalent, albeit at low levels, in Africa and South Asia. Our findings provide further evidence that multidrug-resistant Salmonella Typhimurium ST313 can be carried asymptomatically by humans in sub-Saharan Africa.

Identifiants

pubmed: 33493332
pii: 6119542
doi: 10.1093/cid/ciab051
pmc: PMC8366818
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

631-641

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Bill and Melinda Gates Foundation
ID : 38874
Organisme : Global Challenges Research Fund
Organisme : Earlham Institute
ID : BBS/OS/GC/000009D
Organisme : Core Strategic Program of the Earlham Institute
ID : BB/CCG1720/1
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/CCG1720/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106914/Z/15/Z
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Auteurs

Irene N Kasumba (IN)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Caisey V Pulford (CV)

Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom.

Blanca M Perez-Sepulveda (BM)

Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom.

Sunil Sen (S)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Nurulla Sayed (N)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Jasnehta Permala-Booth (J)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Sofie Livio (S)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Darren Heavens (D)

Earlham Institute, Norwich Research Park, Norwich, United Kingdom.

Ross Low (R)

Earlham Institute, Norwich Research Park, Norwich, United Kingdom.

Neil Hall (N)

Earlham Institute, Norwich Research Park, Norwich, United Kingdom.
School of Biological Sciences, University of East Anglia, Norwich, United Kingdom.

Anna Roose (A)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Helen Powell (H)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Tamer Farag (T)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Sandra Panchalingham (S)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Lynette Berkeley (L)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Dilruba Nasrin (D)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

William C Blackwelder (WC)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Yukun Wu (Y)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Boubou Tamboura (B)

Centre pour le Developpement des Vaccins, Bamako, Mali.

Doh Sanogo (D)

Centre pour le Developpement des Vaccins, Bamako, Mali.

Uma Onwuchekwa (U)

Centre pour le Developpement des Vaccins, Bamako, Mali.

Samba O Sow (SO)

Centre pour le Developpement des Vaccins, Bamako, Mali.

John B Ochieng (JB)

Kenya Medical Research Institute/US Centers for Disease Control and Prevention, Kisumu, Kenya.

Richard Omore (R)

Kenya Medical Research Institute/US Centers for Disease Control and Prevention, Kisumu, Kenya.

Joseph O Oundo (JO)

Kenya Medical Research Institute/US Centers for Disease Control and Prevention, Kisumu, Kenya.

Robert F Breiman (RF)

Kenya Medical Research Institute/US Centers for Disease Control and Prevention, Kisumu, Kenya.

Eric D Mintz (ED)

Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Ciara E O'Reilly (CE)

Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Martin Antonio (M)

Medical Research Council Unit, The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.

Debasish Saha (D)

Medical Research Council Unit, The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.

M Jahangir Hossain (MJ)

Medical Research Council Unit, The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.

Inacio Mandomando (I)

Centro de Investigacao em Saude da Manhica (CISM), Maputo, Mozambique.

Quique Bassat (Q)

Centro de Investigacao em Saude da Manhica (CISM), Maputo, Mozambique.
Catalan Institution for Research and Advanced Studies (ICREA), Pg. Lluís Companys 23, Barcelona, Spain.
Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu (University of Barcelona), Barcelona, Spain.
Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.

Pedro L Alonso (PL)

Centro de Investigacao em Saude da Manhica (CISM), Maputo, Mozambique.
ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Instituto Nacional de Saúde, Ministério de Saúde, Maputo, Mozambique.

T Ramamurthy (T)

National Institute of Cholera and Enteric Diseases, Kolkata, India.

Dipika Sur (D)

National Institute of Cholera and Enteric Diseases, Kolkata, India.

Shahida Qureshi (S)

Department of Pediatrics and Child Health, The Aga Khan University, Karachi, Pakistan.

Anita K M Zaidi (AKM)

Department of Pediatrics and Child Health, The Aga Khan University, Karachi, Pakistan.

Anowar Hossain (A)

International Centre for Diarrhoeal Disease Research, Mohakhali, Dhaka, Bangladesh.

Abu S G Faruque (ASG)

International Centre for Diarrhoeal Disease Research, Mohakhali, Dhaka, Bangladesh.

James P Nataro (JP)

Center for Vaccine Development and Global Health.

Karen L Kotloff (KL)

Center for Vaccine Development and Global Health.
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Myron M Levine (MM)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Jay C D Hinton (JCD)

Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom.

Sharon M Tennant (SM)

Center for Vaccine Development and Global Health.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH